Multiple sclerosis in pregnancy: prevalence, sociodemographic features, and obstetrical outcomes

2017 ◽  
Vol 31 (3) ◽  
pp. 382-387 ◽  
Author(s):  
Alex Fong ◽  
Cindy T. Chau ◽  
Cara Quant ◽  
Jennifer Duffy ◽  
Deyu Pan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Obstetrical Outcomes ◽  
In Pregnancy

scholarly journals Women’s Health: Contemporary Management of MS in Pregnancy and Post-Partum

Biomedicines ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 32 ◽  
Author(s):  
Kelly Tisovic ◽  
Lilyana Amezcua
Keyword(s):  
Multiple Sclerosis ◽  
Post Partum ◽  
Fetal Exposure ◽  
Childbearing Age ◽  
Maternal Complications ◽  
Increased Risk ◽  
Effective Contraception ◽  
Disease Modifying ◽  
Contemporary Management ◽  
In Pregnancy

Multiple sclerosis (MS) primarily affects women in childbearing age and is associated with an increased risk of adverse post-partum outcomes. Relapses and now fetal exposure to disease modifying treatments in the early phase of pregnancy and thereafter are of concern. Safe and effective contraception is required for women who wish to delay or avoid pregnancy while on disease-modifying treatments. Counseling and planning is essential to assess the risk of both fetal and maternal complications, particularly now in the era of highly efficient and riskier therapies. The purpose of this review is to provide a practical framework using the available data surrounding pregnancy in MS with the goal of optimizing outcomes during this phase in MS.

Disease-Modifying Drugs for Multiple Sclerosis in Pregnancy: A Systematic Review (P06.188)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P06.188-P06.188
Author(s):  
E. Lu ◽  
B. W. Wang ◽  
C. Guimond ◽  
A. Synnes ◽  
D. Sadovnick ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
In Pregnancy

scholarly journals Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

Neurology ◽  
2013 ◽  
Vol 80 (11) ◽  
pp. 1068-1069 ◽  
Author(s):  
J. A. Charles ◽  
H. Tremlett ◽  
E. Lu ◽  
C. Guimond ◽  
A. D. Sadovnick
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
In Pregnancy

The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis

2008 ◽  
Vol 14 (4) ◽  
pp. 571-572 ◽  
Author(s):  
Catherine M Dalton ◽  
Elizabeth Keenan ◽  
Louise Jarrett ◽  
Lisa Buckley ◽  
Valerie L Stevenson
Keyword(s):  
Multiple Sclerosis ◽  
Gaba Receptor ◽  
Infusion Pump ◽  
Male Infant ◽  
Intrathecal Baclofen ◽  
Intrathecal Therapy ◽  
General Anesthetic ◽  
First Case ◽  
Severe Spasticity ◽  
In Pregnancy

Intrathecal baclofen is a GABA-receptor agonist and one of the mainstay treatments of severe spasticity due to multiple sclerosis (MS). The authors report a case on the use of intrathecal baclofen administered using a Medtronic Synchromed II infusion pump. A healthy male infant (2.68 kg, Apgars 9 and 10) was born at 36 weeks gestation by cesarean section, under general anesthetic. This is the fifth reported case of intrathecal baclofen administered during pregnancy and adds to the knowledge that thus far it is relatively safe in pregnancy and may in fact be safer for the infant than oral baclofen. This is the first case report of the use of intrathecal baclofen in pregnancy and MS.

Sign in / Sign up

Export Citation Format

Share Document